Introduction
Cancerous tumors are a leading cause of death worldwide ( 1 ). Tumors are classified as primary and secondary. Primary tumors originate from normal cells that undergo malignant transformation due to various internal and external carcinogenic factors and form a cancer cell mass ( 2 ). Malignant cells can leave the primary tumor and spread to other parts or organs of the body via complex mechanisms, resulting in secondary or metastatic cancers ( 2 ). Bone is one of the most common sites of metastasis, with bone metastasis affecting >1.5 million patients worldwide ( 3 ). Bone metastasis frequently occurs in numerous cancers ( 4 ), particularly prostate cancer, breast cancer and lung cancer ( 1 , 5 ). Metastasis is often considered as the terminal stage in the progression of cancer, and tumor cells in the bone microenvironment have been suggested to undergo reprogramming, enabling them to seed secondary metastasis to other organs including the lung, liver, and brain ( 6 ). Once bone metastases occur, they are incurable and lead to severe skeletal-related events, including pathological fractures, pain, compression of the spinal cord or nerves, and disability in patients with advanced bone metastases ( 5 ). These events critically reduce the quality of life of patients with bone metastases and increase medical costs ( 7 ). Therefore, it is urgently necessary to elucidate the mechanisms of bone metastasis, develop animal models to better understand the characteristics of bone metastasis, and identify new therapeutic targets for bone metastasis. The present review focuses on the mechanisms underlying bone metastasis and recent progress in animal models of bone metastasis.
Dynamic cycle of bone remodeling
Bone undergoes dynamic remodeling throughout life ( 8 ) ( Fig. 1 ). This process promotes bone regeneration and repair, which are crucial for the maintenance of bone homeostasis. Dynamic bone remodeling primarily involves osteolysis and bone formation.
Dissolution of bone
The dynamic bone remodeling cycle begins when osteoclast precursors are attracted to sites of bone damage or aging in response to chemokine signaling ( 9 ). These precursors then differentiate and fuse to form multinucleated osteoclasts, which play an osteolytic role. The binding of receptor activator of nuclear factor-κB (RANK) with RANK ligand (RANKL) promotes the fusion, differentiation and maturation of osteoclast precursors ( 10 ). RANK is expressed on the cell surface of osteoclasts and their precursors, while RANKL is produced primarily by osteocytes, osteoblasts, bone marrow stromal cells and activated T cells ( 11 ). Osteoprotegerin (OPG) also binds to RANKL, which prevents RANKL from binding to RANK, thereby blocking RANKL signaling and regulating osteoclastogenesis and osteolysis ( 12 ). In addition, Nozawa et al ( 13 ) demonstrated that cellular communication network factor 2 (CCN2), also known as a connective tissue growth factor, induces osteoclast formation through interaction with integrin αvβ3. CCN2 also regulates dynamic bone remodeling by participation in the RANK-RANKL-OPG system ( 14 ). It has been suggested that bone morphogenetic protein 9 (BMP9) can inhibit bone metastasis in patients with breast cancer by downregulating CCN2 ( 15 ). Following osteoclast differentiation and maturation, cytoskeletal changes lead to the formation of a ruffled border. The osteoclasts then secrete proteolytic enzymes and hydrochloric acid through the ruffled border to facilitate osteolysis ( 15 ).
Formation of bone
Following osteolysis, osteoclasts leave the bone surface and undergo programmed cell death, specifically apoptosis, which signals the beginning of bone formation ( 16 ). Osteoblast precursors are attracted to the site of osteolysis. This process is regulated by the osteoblast precursor transcription factors, including core-binding factor subunit a-1, also known as Runt-related transcription factor 2 (RUNX2), and osterix, which bind to osteoblast-specific gene enhancers to promote the development of an osteoblast-like phenotype ( 17 ). In addition, BMPs promote the proliferation and differentiation of osteoblast precursors ( 18 ), and Wnt family proteins promote bone formation via the activation of low-density lipoprotein receptor-related protein 5 (LRP5), RUNX2 and osterix ( 19 ). However, sclerostin (Sost) produced by osteocytes inhibits bone formation by antagonizing the effects of Wnt proteins ( 20 ). Mature osteoblasts secrete noncalcified bone matrix onto the bone surface, which subsequently mineralizes to form mature bone. During this process, some osteoblasts are trapped by mineralized bone and differentiate into osteocytes. Osteocytes are linked together by elongated cytoplasmic extensions, which allows them to transmit signals, such as mechanical loading signals, via nitric oxide and prostaglandin signaling molecules ( 21 ).
Dynamic bone remodeling continues when bone formation is complete. Various factors influence this dynamic process, which can be classified into two categories: i) Chemical factors or hormones and ii) physical factors ( 22 ). Inflammatory factors such as IL-1 and tumor necrosis factor accelerate the remodeling cycle. Hormones that regulate calcium levels, such as 1,25-dihydroxyvitamin D and parathyroid hormone, promote bone remodeling and mobilize bone calcium to maintain blood calcium levels ( 23 ). While thyroid and growth hormones promote bone remodeling ( 24 ), estrogens and androgens inhibit bone resorption and promote bone formation, particularly in the trabecular and endocortical skeletal compartments ( 25 ). These factors regulate bone remodeling primarily by modulating the RANK-RANKL-OPG signaling pathway ( 26 ). Notably, mechanical loading affects bone remodeling; for example, increased mechanical loading increases bone formation and reduces osteolysis.
Physiological changes during cancer bone metastasis
Bone metastasis has two main phenotypes: Osteolytic and osteogenic. Most bone metastases exhibit both osteolytic and osteogenic characteristics, with one phenotype being dominant. For example, breast and lung cancers are frequently osteolytic, while prostate cancer is frequently osteoblastic. Osteolytic lesions are distinguished primarily by bone destruction, which generally appears as cortical cavitation when analyzed using radiographic imaging. By contrast, osteoblastic lesions are distinguished by the excessive formation of new bone, which results in increased bone density on imaging, frequently described as osteosclerosis on the bone surface ( 2 ).
Mechanisms of osteolytic metastasis
Tumor osteolytic microenvironment
Bone remodeling involves a variety of cytokines, growth factors and cell adhesion molecules, which makes bone an attractive location for metastatic tumor cells ( Fig. 2 ). The epiphysis, with its rich blood supply and trabecular bone structure, provides an ideal environment for the survival of bone metastatic cells ( 27 ). The slow blood flow in sinusoid vessels further facilitates the colonization of the bone marrow by hematopoietic stem cells and invasive tumor cells. Additionally, endothelial cells in sinusoidal vessels express a variety of adhesion molecules, including E-selectin, P-selectin, intracellular adhesion molecules and vascular cell adhesion molecules (VCAMs), which promote the homing of tumor cells to the bone marrow ( 28 – 30 ). Following tumor colonization of the bone, the bone microenvironment facilitates tumor growth and invasion. Various resident and transient cells, including stromal cells, osteoblasts and immune cells, affect tumor survival. Stromal cells, which originate from mesenchymal cells within the bone marrow and include adipocytes, fibroblasts and osteoblasts, promote tumor cell proliferation and differentiation via the secretion of VCAMs, syndecan and matrix metalloproteinase 2 (MMP-2) ( 31 ). Osteoclast-mediated osteolysis further promotes tumor growth by releasing growth factors from the bone, which increase tumor cell proliferation and osteolysis. Transient cells, including red blood cells, platelets, and T cells, also promote tumor growth and metastasis via a variety of pathways and molecular interactions ( 28 ).
RANK-RANKL-OPG system
The RANK-RANKL-OPG system plays a crucial role in the promotion of cancer cell proliferation, epithelial-mesenchymal transition (EMT) and bone metastasis ( 32 , 33 ). Tumor cells secrete various cytokines within the bone microenvironment that affect the RANK-RANKL-OPG system ( 34 ). Tumor-derived parathyroid hormone-related protein (PTHrP), insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF) and platelet-derived growth factor not only increase tumor cell growth in an autocrine manner but also promote the production and release of RANKL by osteoblasts and stromal cells ( 35 ). In addition, tumor-derived PTHrP, IL-1, prostaglandin E2, BMP and epithelial growth factor downregulate OPG expression in the stroma and osteoblasts ( 36 ). Accordingly, RANKL levels increase and OPG levels decrease in the tumor bone microenvironment, which disrupts the dynamic balance of bone remodeling. The binding of RANKL to RANK promotes the fusion, differentiation and maturation of osteoclast precursors through mitogen-activated protein kinase (MAPK) and nuclear factor-κB signaling pathways, and enhances osteolysis through c-Src signaling ( 37 , 38 ). In addition, PTHrP stimulates the secretion of MMP-13 via the protein kinase C (PKC)-ERK signaling pathway, and MMP-13 contributes to bone degradation and bone fractures ( 39 ).
Transforming growth factor-β (TGF-β) plays a dual role
TGF-β acts as a suppressor in the early stages of tumorigenesis but promotes tumor progression in later stages ( 40 ). Bone metastasis occurs at an advanced stage of cancer, and TGF-β plays a key role in bone metastasis and the promotion of tumor development. TGF-β is primarily released into the bone microenvironment by osteolysis, and mediates the EMT, invasion, angiogenesis and immunosuppression of tumor cells via TGF-β/Smad signaling ( 41 , 42 ). Integrin αvβ3 has been demonstrated to be required for the TGF-β/Smad signaling that triggers breast cancer metastasis ( 43 ), but the underlying mechanism remains to be further elucidated. Tumor cells undergoing EMT experience cytoskeletal rearrangement and loss of intercellular adhesion, ultimately increasing their invasion, motility and metastatic potential. Preclinical experiments have shown that TGF-β inhibitors have the ability to inhibit bone metastases in animal models of breast cancer, but their effectiveness is limited in lung cancer ( 44 ). These findings suggest that the mechanism of TGF-β in bone metastases varies according to the primary tumor type, highlighting that further studies are necessary to classify primary tumors based on their mechanism of metastasis.
Mechanisms of osteoblastic metastasis
Wnt-LRP5-β-catenin pathway
Tumor cells interact with osteoblasts, leading to the production of TGF-β, BMP, IGF and FGF. This interaction also promotes Wnt signaling, which induces osteogenic activity ( Fig. 3 ). TGF-β and BMP activate Smad signaling in osteoblasts, while growth factors activate MAPK and PKC signaling in osteoclasts. In addition, Wnt activates the β-catenin regulatory signaling pathway. These pathways converge and interact with the RUNX2 transcriptional network to induce osteoblast differentiation and proliferation. Research has shown that the Wnt/β-catenin pathway is crucial for osteoblast function and bone formation, with activation of this pathway stimulating osteoblast development and promoting bone formation ( 45 ). Osteocytes secrete Sost, which binds to LRP5, thereby blocking the Wnt-LRP5-β-catenin pathway and inhibiting bone formation. The serum level of Sost is upregulated in patients with multiple myeloma, as myeloma cells secrete Sost; therefore, patients with multiple myeloma frequently present with osteolytic lesions. In vitro data suggest that breast cancer cells induce Sost expression to inhibit bone metastasis and osteogenesis; however, in prostate cancer, Sost expression is downregulated while BMP-6 expression is upregulated ( 46 ).
Dickkopf-1 (DKK-1) can also bind to LRP5 to inhibit Wnt signaling ( 47 ). Endothelin-1 (ET-1) and PTHrP mediate bone formation. ET-1 is one of four isoforms of ET, the activity of which is regulated by the proteolytic conversion of an inactive precursor to an active form ( 48 ). Prostate epithelial cells and most prostate cancer cell lines have been indicated to secrete a substantial amount of ET-1, and plasma ET-1 concentrations are elevated in patients with advanced prostate cancer. ET-1 secreted by prostate bone metastases binds to ET receptor A on osteoblasts, which stimulates their proliferation and osteogenesis via β-catenin and MAPK ( 49 ). Activated osteoblasts in the bone microenvironment release factors that stimulate tumor cell proliferation and invasion ( 50 ). In addition, tumor cell-derived ET-1 promotes osteogenesis in osteoblasts via the inhibition of DKK-1 synthesis ( 51 ). Notably, the N-terminal fragment of PTHrP can mimic the binding of ET-1 to the endothelin receptors in osteoblasts to promote bone formation ( 52 ). Furthermore, prostate specific antigen (PSA) can suppress the osteolytic effect of PTHrP ( 53 ).
RANK-RANKL-OPG system
Downregulation of the RANKL-to-OPG ratio in the RANK-RANKL-OPG system can inhibit osteolysis and lead to an osteogenic phenotype. In prostate cancer, PSA has been shown to inhibit osteolytic activity by inhibiting the expression of RANKL in osteoblasts and promoting the function of osteoblasts ( 54 ). In addition, the expression levels of RANK and RANKL in tumor tissue from patients with metastatic prostate cancer are significantly higher compared with those in patients with local disease ( 55 ). Notably, RANKL-induced osteolysis appears to facilitate the colonization of osteoblastic bone metastatic tumor cells ( 56 ). The ability of RANKL to promote the intraosseous growth of prostate cancer cells has been found to be associated with IGF signaling and hypoxia-inducible factors, which create a bone microenvironment favorable for tumor growth ( 57 ).
In general, the mechanisms underlying the behavior of cancer cells in bone metastasis are highly complex and largely unknown, despite decades of research. Additional research, as well as effective and suitable animal models, are required to elucidate the specific mechanisms and identify novel therapeutic targets.
Animal models of cancer bone metastasis
Cancer is the second leading cause of human death worldwide, after cardiovascular diseases, with metastases typically being the cause of mortality and bone being the most prevalent site of metastasis ( 58 ). Bone metastases are common among patients with breast, prostate or lung cancer, and may also occur in patients with other tumors, including myeloma, renal and thyroid cancers, Ewing's sarcoma and lymphoma ( 59 , 60 ). The general pathogenesis of bone metastasis involves several stages, including primary tumor proliferation, local tissue invasion, intravascular invasion, extravasation into the bone marrow, tumor cell dormancy, intraosseous proliferation and changes in the intraosseous microenvironment. In 1889, Stephen Paget proposed the ‘seed and soil’ hypothesis ( 61 ). This hypothesis proposes that the interaction between cancer cells and the organ microenvironment influences cancer cell proliferation, survival and expansion, and that the ability of the cancer cells to recruit a blood supply determines whether the cancer cells will metastasize. Understanding the molecular pathways involved in cancer metastasis is crucial for preventing the formation and growth of bone metastases. Animal models of bone metastasis are essential for investigating these molecular pathways. An ideal animal model should be clinically relevant, mimic human disease, and reproducible. However, each model has both advantages and disadvantages, and no single model is perfect. Researchers must choose the most appropriate model based on the specific research question.
Advantages and disadvantages of different routes of inoculation for modeling cancer bone metastasis
The injection techniques that are commonly used to study bone metastasis include tail vein, intracardiac, intraosseous, orthotopic, subcutaneous and tail artery injections. Each type of bone metastasis model offers unique benefits and limitations. Therefore, it is critical to choose a model that is suitable for the specific research direction and purpose.
Tail vein injection is a relatively simple method of injection that is primarily used in studies of tumor blood circulation and lung metastasis. This injection method rarely leads to bone metastasis but more frequently leads to lung metastasis ( 62 ).
Intracardiac inoculation typically involves injecting tumor cells into the left ventricle of mice, allowing the cells to circulate systemically and spread to the bone to establish bone metastases. This type of model has a high tumorigenicity and a short modeling time, allowing the distribution of tumor cells to be monitored in real-time using bioluminescence imaging when fluorescently labeled tumor cells are injected. It is the most frequently used animal model of bone metastasis. However, the successful construction of this model is challenging. In addition, as tumor cells spread throughout the body via the systemic circulation, multiple metastases can develop, sometimes leading to fatal non-bone metastases before bone metastasis occurs, which may complicate the specific study of bone metastasis ( 63 ).
Intraosseous injection involves directly injecting tumor cells into the femur or tibia, leading to tumor formation in the bone. Compared with left ventricular injection, intraosseous injection results in a higher incidence of bone metastasis and a shorter experimental period. However, it also disrupts the integrity of the bone, which makes it less suitable for studying the molecular mechanism of bone metastasis ( 64 ). In addition, as it does not involve metastasis, with the movement of cells from a primary site to the bone, this model is not strictly a model of metastasis. However, it can be used for the investigation of tumor-bone interactions.
Orthotopic inoculation is a surgical method in which tumor cells or tumor masses are directly inoculated into the organs of mice, such as the prostate and mammary glands. Compared with the spontaneous canine bone metastasis model, this method has greater tumorigenicity and shorter latency while retaining the biological characteristics of tumor cells. It can effectively simulate the whole process of tumor metastasis from the primary site to the bone. However, in numerous cases, mice in this model develop lung and lymph node metastases before bone metastasis, and succumb to other causes before bone metastases can develop.
Subcutaneous inoculation is a method of injecting tumor cells or tumor fragments into the skin of mice to form tumors. This method is simple and easy to manage; however, it rarely causes bone metastasis, even when using cells derived from the bone metastases of patients ( 65 ). Currently, subcutaneous tumor models are primarily derived from patient samples and are used to evaluate the inhibitory effects of antitumor drugs against human tumors ( 66 ).
Caudal artery injection ( 63 ) delivers tumor cells directly into the tail artery of a mouse. This method is relatively easy to perform and effectively transfers cancer cells to the posterior limb bone. It is more efficient than intracardiac injection, and markedly shortens the time taken for bone metastasis to develop. Furthermore, tail artery injection rarely causes acute mortality, which allows researchers to inject a higher number of cancer cells, which accelerates the development of bone metastasis for multiple cell lines. However, this method may cause some tumor cells to metastasize to the lung, which complicates the study of bone metastasis. Table I summarizes the methods used to model bone metastasis via the caudal artery injection of tumor cells ( 63 , 67 – 71 ).
Cell lines and methods for establishing animal models of cancer bone metastasis Prostate cancer
To date, dogs are the only nonrodent animals known to develop spontaneous prostate cancer. However, their use in research is challenging due to difficulties in experimental control, the low incidence of spontaneous tumor formation and bone metastasis, and the high cost ( 72 ). Lobund-Wistar rats, ACI/segHapBR rats, C57BL/6 mice, BALB/c nude mice, severe combined immunodeficiency mice and various transgenic mouse models have been used to investigate bone metastasis in prostate cancer ( 73 – 75 ). However, bone metastasis in rat prostate cancer models is very rare. Due to their short experimental period, low economic cost and research convenience, mice have become the most commonly used animals for studying prostate cancer bone metastasis.
One of the most commonly used prostate cancer cell lines is PC3, which was isolated in 1979 from a bone metastatic lesion in a 62-year-old White male patient with grade IV prostate cancer ( 76 ). This cell line has high metastatic potential and exhibits characteristics more typical of neuroendocrine carcinoma than adenocarcinoma ( 77 ). Numerous PC3 cell sublines now exist, and PC3 cells can be reimplanted in vivo to screen for highly metastatic variants. In 1984, Kozlowski et al ( 78 ) injected PC3 cells into nude mice and subsequently harvested metastatic cells from the liver, which were designated PC3M cells. Later, in 1996, Pettaway et al ( 79 ) orthotopically injected PC3M cells into the prostate of mice, and subsequently isolated metastatic cells from the lymph nodes and used them to establish a PC3M-LN4 cell subline.
DU145 cells were originally derived from the brain of a 69-year-old White male patient with metastatic prostate cancer ( 80 ). In immunodeficient mice, the intratibial or intracardiac injection of DU145 cells leads to the formation of lytic bone lesions ( 77 ). DU145 cells offer advantages in the study of prostate cancer, as their resemblance to adenocarcinoma is closer than that of PC3 cells, and they are capable of producing bone metastases in vivo . DU145 cell-derived bone metastases, like those of PC3, are osteolytic ( 77 ).
LNCaP cells were established by Horoszewicz ( 81 ) in 1977 via isolation from the left supraclavicular lymph node of a 50-year-old White male patient with metastatic prostate cancer. In a subsequent study, LNCaP cells were inoculated in castrated mice until bone metastases developed; these resulting cells were collected and designated as LNCaP C4-2B ( 82 ). LNCaP C4-2B cells exhibit androgen-independent characteristics and have greater metastatic potential than the parental LNCaP cell line, as they form mixed osteolytic-osteogenic lesions in immunodeficient mice when injected via intraosseous or intracardiac routes ( 77 , 83 ).
Breast cancer
Bone is one of the most prevalent sites for breast cancer metastasis in females. Bone metastases in breast cancer are often osteolytic and associated with high morbidity and mortality rates; ~80% of patients with advanced breast cancer develop bone metastases ( 84 ). The median survival time of patients with breast cancer bone metastasis is only 36 months ( 85 ). However, animal models have contributed to improvements in the treatment of bone metastasis in patients with breast cancer ( 86 ). Mice, rats, cats and dogs frequently develop spontaneous benign and malignant mammary tumors. However, these spontaneous breast cancers are usually unsuitable for studying bone metastasis as most spontaneous breast tumors in mice and rats do not metastasize, instead causing only local invasion ( 87 ). Furthermore, the majority of breast adenocarcinomas in rodents rapidly lose estrogen responsiveness ( 88 ), making them unsuitable models for the study of estrogen-responsive female breast cancer.
MDA-MB-231 cells were originally isolated from the breast of a 40-year-old White female patient with breast cancer, and are commonly used in bone metastasis research. MDA-MB-231 and its bone metastatic subline have been used in intracardiac, in situ , intraosseous and caudal vein injection studies. These cells metastasize almost entirely to the bone and cause osteolytic metastasis 3–4 weeks after injection. Bisphosphonates have been demonstrated to reduce the formation of new bone metastases from MDA-MB-231 in animal models, and to hinder the growth of existing bone metastases ( 89 ).
MCF7 cells are breast adenocarcinoma cells isolated from the pleural effusion of a 69-year-old White female patient. These cells express estrogen receptors and can generate mixed osteolytic or osteogenic bone metastases following intraosseous injection. Bone metastasis develops gradually, potentially taking up to 6 months after intracardial injection ( 90 ).
ZR-75-1 cells were isolated from the breast tissue of a 63-year-old White female patient with ductal breast cancer. These cells have been used to establish an osteoblastic breast cancer bone metastasis model in nude mice via intracardiac injection. This model was used to demonstrate the critical involvement of ET-1 in the pathophysiology of osteoblastic metastasis ( 91 ).
4T1 is a mammary tumor cell line derived from spontaneous mammary tumors in BALB/c mice. These cells are highly invasive and tumorigenic, with growth and metastatic spread patterns very similar to those of human breast cancer ( 92 ). 4T1 cells can easily be transplanted into the mammary gland, allowing the primary tumor to grow in the anatomically correct site, closely mimicking the metastatic pattern observed in human breast cancer. In addition, the course of 4T1 metastasis to lymph nodes and other organs is very similar to that of human breast cancer ( 93 ). Tumors often form on days 7–10 following the orthotopic injection of 4T1 cells into the mammary fat pads of female BALB/c mice, with metastasis to the bone and internal organs occurring 3–4 weeks later. Although the incidence of bone metastasis following the orthotopic injection of 4T1 cells can reach 100%, the reliability of this model is poor ( 94 ).
Lung cancer
Lung cancer is classified into two subtypes: Small cell lung cancer and non-small cell lung cancer, each with distinct biological behaviors, clinical courses and treatment responses. Bone metastases occur in 30–40% of patients with lung cancer ( 95 ). These metastases are primarily osteolytic lesions, osteoblastic lesions and mixed bone lesions ( 96 , 97 ). Several cell lines, including A549, ACC-LC319, H460, H727, H2030, HARA, LLC, SBC-3, NCI-H292, PC9, PC14, SBC-5 and SPC-A-1, have been used in lung cancer bone metastasis animal models ( 98 ). Orthotopic, tail vein, intraosseous and intracardiac injections have all been used in models of bone metastasis in lung cancer; however, orthotopic injection more closely replicates the biological behavior of lung cancer metastasis compared with other methods. Intraosseous injections can be administered to the tibia or spinal canal, and the direct injection of PC14 cells into the spinal canal of mice was found to result in spinal metastases of lung cancer ( 99 ). The osteoporosis and spinal compression caused by bone metastases in this model closely resemble those observed with human spinal metastases. Certain cell lines can be selectively cultured in vivo to generate sublines that more readily metastasize to the bone. For example, although the bone metastasis of PC14 cells in mice is rare, multiple in vivo selective cultures enabled a highly metastatic PC14HM subline to be established ( 100 ). Similarly, following eight cycles of in vivo selection of the SPC-A-1 cell line, the SPC-A-1-BM cell subline achieved a bone metastasis success rate of 100% in mice following intracardiac injection ( 101 ). Table II summarizes the specific conditions of the cell lines and modeling methods commonly used for studying bone metastases ( 77 , 85 , 86 , 102 – 120 ).
Conclusion and perspectives
Direct cell injection is the most frequently used approach for the development of bone metastasis models, with intracardiac and intraosseous injection methods being the most successful in bone metastasis research. Tail vein injection is simpler than cardiac injection but frequently leads to lung metastasis, which complicates the study of bone metastasis. Although cell injection models are straightforward and easy to maintain, they provide limited information about the process by which tumors metastasize to bone. Animal models are very important in the study of the pathogenesis of bone metastasis. The development of different animal models for different research purposes and research directions is critical. The identification of key targets for the treatment of bone metastasis may improve therapy efficacy and patient quality of life, and ultimately extend patient survival.
Acknowledgements
Not applicable.
Availability of data and materials
Not applicable.
Authors' contributions
MD, JG and GQ were responsible for conception and design. JG and GQ supervised the study. MD, YZ and HD wrote the original manuscript. JG, GQ and MD reviewed and edited the manuscript. All authors read and approved the final version of the manuscript. Data authentication is not applicable.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
References
1 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A Bray F Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209 249 2021 10.3322/caac.21660 33538338
2 Coleman RE Croucher PI Padhani AR Clézardin P Chow E Fallon M Guise T Colangeli S Capanna R Costa L Bone metastases Nat Rev Dis Primers 6 83 2020 10.1038/s41572-020-00216-3 33060614
3 Clézardin P Coleman R Puppo M Ottewell P Bonnelye E Paycha F Confavreux CB Holen I Bone metastasis: Mechanisms, therapies, and biomarkers Physiol Rev 101 797 855 2021 10.1152/physrev.00012.2019 33356915
4 Papalia GF Brigato P Sisca L Maltese G Faiella E Santucci D Pantano F Vincenzi B Tonini G Papalia R Denaro V Artificial intelligence in detection, management, and prognosis of bone metastasis: A systematic review Cancers (Basel) 16 2700 2024 10.3390/cancers16152700 39123427 PMC11311270
5 Sousa S Clézardin P Bone-targeted therapies in Cancer-induced bone disease Calcif Tissue Int 102 227 250 2018 10.1007/s00223-017-0353-5 29079995
6 Zhang W Bado IL Hu J Wan YW Wu L Wang H Gao Y Jeong HH Xu Z Hao X The bone microenvironment invigorates metastatic seeds for further dissemination Cell 184 2471 86.e20 2021 10.1016/j.cell.2021.03.011 33878291 PMC8087656
7 Coleman R Hadji P Body JJ Santini D Chow E Terpos E Oudard S Bruland Ø Flamen P Kurth A Bone health in cancer: ESMO Clinical Practice Guidelines Ann Oncol 31 1650 1663 2020 10.1016/j.annonc.2020.07.019 32801018
8 Trompet D Melis S Chagin AS Maes C Skeletal stem and progenitor cells in bone development and repair J Bone Miner Res 39 633 654 2024 10.1093/jbmr/zjae069 38696703
9 Boyce BF Advances in the regulation of osteoclasts and osteoclast functions J Dent Res 92 860 867 2013 10.1177/0022034513500306 23906603 PMC3775372
10 Ikebuchi Y Aoki S Honma M Hayashi M Sugamori Y Khan M Kariya Y Kato G Tabata Y Penninger JM Coupling of bone resorption and formation by RANKL reverse signalling Nature 561 195 200 2018 10.1038/s41586-018-0482-7 30185903
11 Yamagishi T Kawashima H Ogose A Ariizumi T Oike N Sasaki T Hatano H Ohashi R Umezu H Ajioka Y Endo N Expression profiling of Receptor-activator of nuclear Factor-Kappa B ligand in soft tissue tumors Tohoku J Exp Med 248 87 97 2019 10.1620/tjem.248.87 31189751
12 Gostage J Kostenuik P Goljanek-Whysall K Bellantuono I McCloskey E Bonnet N Extra-osseous roles of the RANK-RANKL-OPG axis with a focus on skeletal muscle Curr Osteoporos Rep 22 632 650 2024 10.1007/s11914-024-00890-2 39325366 PMC11499344
13 Nozawa K Fujishiro M Kawasaki M Kaneko H Iwabuchi K Yanagida M Suzuki F Miyazawa K Takasaki Y Ogawa H Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis Arthritis Res Ther 11 R174 2009 10.1186/ar2863 19922639 PMC3003536
14 Aoyama E Kubota S Khattab HM Nishida T Takigawa M CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG Bone 73 242 248 2015 10.1016/j.bone.2014.12.058 25554597
15 Ren W Sun X Wang K Feng H Liu Y Fei C Wan S Wang W Luo J Shi Q BMP9 inhibits the bone metastasis of breast cancer cells by downregulating CCN2 (connective tissue growth factor, CTGF) expression Mol Biol Rep 41 1373 1383 2014 10.1007/s11033-013-2982-8 24413988
16 Sims NA Martin TJ Coupling the activities of bone formation and resorption: A multitude of signals within the basic multicellular unit Bonekey Rep 3 481 2014 10.1038/bonekey.2013.215 24466412 PMC3899560
17 Nakashima K Zhou X Kunkel G Zhang Z Deng JM Behringer RR de Crombrugghe B The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation Cell 108 17 29 2002 10.1016/S0092-8674(01)00622-5 11792318
18 Garcia J Delany AM MicroRNAs regulating TGFβ and BMP signaling in the osteoblast lineage Bone 143 115791 2021 10.1016/j.bone.2020.115791 33285257 PMC7787082
19 Caetano-Lopes J Canhão H Fonseca JE Osteoblasts and bone formation Acta Reumatol Port 32 103 110 2007 17572649
20 Abhishek Shah A Chand D Ahamad S Porwal K Chourasia MK Mohanan K Srivastava KR Chattopadhyay N Therapeutic targeting of Wnt antagonists by small molecules for treatment of osteoporosis Biochem Pharmacol 230 116587 2024 10.1016/j.bcp.2024.116587 39447984
21 van't Hof RJ Ralston SH Nitric oxide and bone Immunology 103 255 261 2001 10.1046/j.1365-2567.2001.01261.x 11454054 PMC1783253
22 Danilchenko S Kalinkevich A Zhovner M Kuznetsov V Li H Wang J Anisotropic aspects of solubility behavior in the demineralization of cortical bone revealed by XRD analysis J Biol Phys 45 77 88 2019 10.1007/s10867-018-9516-5 30612228 PMC6408563
23 Kitcharanant N Chattipakorn N Chattipakorn SC The effect of intermittent parathyroid hormone on bone lengthening: Current evidence to inform future effective interventions Osteoporos Int 34 1657 1675 2023 10.1007/s00198-023-06809-4 37286663
24 Niwczyk O Grymowicz M Szczęsnowicz A Hajbos M Kostrzak A Budzik M Maciejewska-Jeske M Bala G Smolarczyk R Męczekalski B Bones and hormones: Interaction between hormones of the hypothalamus, pituitary, adipose tissue and bone Int J Mol Sci 24 6840 2023 10.3390/ijms24076840 37047811 PMC10094866
25 Grigoryan S Clines GA Hormonal control of bone architecture throughout the lifespan: Implications for fracture prediction and prevention Endocr Pract 30 687 694 2024 10.1016/j.eprac.2024.04.006 38631489
26 Nagy V Penninger JM The RANKL-RANK Story Gerontology 61 534 542 2015 10.1159/000371845 25720990
27 Mastro AM Gay CV Welch DR The skeleton as a unique environment for breast cancer cells Clin Exp Metastasis 20 275 284 2003 10.1023/A:1022995403081 12741685
28 Bussard KM Gay CV Mastro AM The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27 41 55 2008 10.1007/s10555-007-9109-4 18071636
29 Sharma R Sharma R Khaket TP Dutta C Chakraborty B Mukherjee TK Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1 Cell Oncol (Dordr) 40 199 208 2017 10.1007/s13402-017-0324-x 28534212 PMC13001545
30 Chen Q Massagué J Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis Clin Cancer Res 18 5520 555 2012 10.1158/1078-0432.CCR-11-2904 22879387 PMC3473104
31 Lipton A Implications of bone metastases and the benefits of bone-targeted therapy Semin Oncol 37 (Suppl 2) S15 S29 2010 10.1053/j.seminoncol.2010.10.002 21111244
32 De Leon-Oliva D Barrena-Blázquez S Jiménez-Álvarez L Fraile-Martinez O García-Montero C López-González L Torres-Carranza D García-Puente LM Carranza ST Álvarez-Mon MÁ The RANK-RANKL-OPG System: A multifaceted regulator of homeostasis, immunity, and cancer Medicina (Kaunas) 59 1752 2023 10.3390/medicina59101752 37893470 PMC10608105
33 Wang Y Liu Y Huang Z Chen X Zhang B The roles of osteoprotegerin in cancer, far beyond a bone player Cell Death Discov 8 252 2022 10.1038/s41420-022-01042-0 35523775 PMC9076607
34 Clézardin P The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: Physiopathology and clinical implications Bull Cancer 98 837 846 2011 (In French) 10.1684/bdc.2011.1398 21700551
35 Roodman GD Mechanisms of bone metastasis N Engl J Med 350 1655 1664 2004 10.1056/NEJMra030831 15084698
36 Susperregui AR Viñals F Ho PW Gillespie MT Martin TJ Ventura F BMP-2 regulation of PTHrP and osteoclastogenic factors during osteoblast differentiation of C2C12 cells J Cell Physiol 216 144 152 2008 10.1002/jcp.21389 18247361
37 Izawa T Zou W Chappel JC Ashley JW Feng X Teitelbaum SL c-Src links a RANK/αvβ3 integrin complex to the osteoclast cytoskeleton Mol Cell Biol 32 2943 2953 2012 10.1128/MCB.00077-12 22615494 PMC3416198
38 Zhou S Li J Ying T Wang Y Wang Q Li X Zhao F StemRegenin 1 attenuates the RANKL-induced osteoclastogenesis via inhibiting AhR-c-src-NF-κB/p-ERK MAPK-NFATc1 signaling pathway iScience 27 109682 2024 10.1016/j.isci.2024.109682 38660403 PMC11039397
39 Ibaragi S Shimo T Iwamoto M Hassan NM Kodama S Isowa S Sasaki A Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells Anticancer Res 30 5029 5036 2010 21187486
40 Giarratana AO Prendergast CM Salvatore MM Capaccione KM TGF-β signaling: Critical nexus of fibrogenesis and cancer J Transl Med 22 594 2024 10.1186/s12967-024-05411-4 38926762 PMC11201862
41 Juárez P Guise TA TGF-β in cancer and bone: Implications for treatment of bone metastases Bone 48 23 29 2011 10.1016/j.bone.2010.08.004 20699127
42 Fan C Wang Q Kuipers TB Cats D Iyengar PV Hagenaars SC Mesker WE Devilee P Tollenaar RAEM Mei H Ten Dijke P LncRNA LITATS1 suppresses TGF-β-induced EMT and cancer cell plasticity by potentiating TβRI degradation EMBO J 42 e112806 2023 10.15252/embj.2022112806 36994542 PMC10183827
43 Li Y Drabsch Y Pujuguet P Ren J van Laar T Zhang L van Dam H Clément-Lacroix P Ten Dijke P Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models Breast Cancer Res 17 28 2015 10.1186/s13058-015-0537-8 25849225 PMC4381510
44 Luis-Ravelo D Antón I Vicent S Zandueta C Martínez S Valencia K Ormazábal C Lecanda F Divergent effects of TGF-β inhibition in bone metastases in breast and lung cancer Rev Osteoporos Metab Miner 5 79 84 2013 10.4321/S1889-836X2013000200004
45 Zhu S Chen W Masson A Li YP Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis Cell Discov 10 71 2024 10.1038/s41421-024-00689-6 38956429 PMC11219878
46 Gkotzamanidou M Dimopoulos MA Kastritis E Christoulas D Moulopoulos LA Terpos E Sclerostin: A possible target for the management of cancer-induced bone disease Expert Opin Ther Targets 16 761 769 2012 10.1517/14728222.2012.697154 22762409
47 Pinzone JJ Hall BM Thudi NK Vonau M Qiang YW Rosol TJ Shaughnessy JD The role of Dickkopf-1 in bone development, homeostasis, and disease Blood 113 517 525 2009 10.1182/blood-2008-03-145169 18687985 PMC2628360
48 Irani S Salajegheh A Smith RA Lam AK A review of the profile of endothelin axis in cancer and its management Crit Rev Oncol Hematol 89 314 321 2014 10.1016/j.critrevonc.2013.08.011 24035584
49 Bagnato A Loizidou M Pflug BR Curwen J Growcott J Role of the endothelin axis and its antagonists in the treatment of cancer Br J Pharmacol 163 220 233 2011 10.1111/j.1476-5381.2011.01217.x 21232046 PMC3087127
50 Xin Z Qin L Tang Y Guo S Li F Fang Y Li G Yao Y Zheng B Zhang B Immune mediated support of metastasis: Implication for bone invasion Cancer Commun (Lond) 44 967 991 2024 10.1002/cac2.12584 39003618 PMC11492328
51 Ma X Yu J Role of the bone microenvironment in bone metastasis of malignant tumors-therapeutic implications Cell Oncol (Dordr) 43 751 761 2020 10.1007/s13402-020-00512-w 32623700 PMC12990750
52 Baldessari C Pipitone S Molinaro E Cerma K Fanelli M Nasso C Oltrecolli M Pirola M D'Agostino E Pugliese G Bone metastases and health in prostate cancer: From pathophysiology to clinical implications Cancers (Basel) 15 1518 2023 10.3390/cancers15051518 36900309 PMC10000416
53 Zhang X Jiang P Wang C The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: A literature review Front Oncol 13 1127637 2023 10.3389/fonc.2023.1127637 37746292 PMC10513387
54 Yonou H Horiguchi Y Ohno Y Namiki K Yoshioka K Ohori M Hatano T Tachibana M Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts Prostate 67 840 848 2007 10.1002/pros.20574 17394194
55 Christoph F König F Lebentrau S Jandrig B Krause H Strenziok R Schostak M RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease World J Urol 36 187 192 2018 10.1007/s00345-017-2145-y 29204705
56 Kuchimaru T Hoshino T Aikawa T Yasuda H Kobayashi T Kadonosono T Kizaka-Kondoh S Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia Cancer Sci 105 553 559 2014 10.1111/cas.12391 24597654 PMC4317828
57 Jin R Sterling JA Edwards JR DeGraff DJ Lee C Park SI Matusik RJ Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone PLoS One 8 e60983 2013 10.1371/journal.pone.0060983 23577181 PMC3618119
58 Choi SW Sun AK Cheung JP Ho JC Circulating tumour cells in the prediction of bone metastasis Cancers (Basel) 16 252 2024 10.3390/cancers16020252 38254743 PMC10813668
59 Roth ES Fetzer DT Barron BJ Joseph UA Gayed IW Wan DQ Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression BMC Cancer 9 274 2009 10.1186/1471-2407-9-274 19664211 PMC2734866
60 Uccella S Morris JM Bakkum-Gamez JN Keeney GL Podratz KC Mariani A Bone metastases in endometrial cancer: Report on 19 patients and review of the medical literature Gynecol Oncol 130 474 482 2013 10.1016/j.ygyno.2013.05.010 23685013 PMC3917308
61 Paget S The distribution of secondary growths in cancer of the breast. 1889 Cancer Metastasis Rev 8 98 101 1989 2673568
62 Elkin M Vlodavsky I Tail vein assay of cancer metastasis Curr Protoc Cell Biol Chapter 19:19.2.1-19.2.7. 2001 doi: 10.1002/0471143030.cb1902s12 10.1002/0471143030.cb1902s12 18228345
63 Kuchimaru T Kataoka N Nakagawa K Isozaki T Miyabara H Minegishi M Kadonosono T Kizaka-Kondoh S A reliable murine model of bone metastasis by injecting cancer cells through caudal arteries Nat Commun 9 2981 2018 10.1038/s41467-018-05366-3 30061695 PMC6065368
64 Neudert M Fischer C Krempien B Bauss F Seibel MJ Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: Model characterisation and in vivo effects of ibandronate on tumour growth Int J Cancer 107 468 477 2003 10.1002/ijc.11397 14506749
65 Hoffman RM Patient-derived orthotopic xenografts: Better mimic of metastasis than subcutaneous xenografts Nat Rev Cancer 15 451 452 2015 10.1038/nrc3972 26422835
66 Stribbling SM Ryan AJ The cell-line-derived subcutaneous tumor model in preclinical cancer research Nat Protoc 17 2108 2128 2022 10.1038/s41596-022-00709-3 35859135
67 Farhoodi HP Segaliny AI Wagoner ZW Cheng JL Liu L Zhao W Optimization of a syngeneic murine model of bone metastasis J Bone Oncol 23 100298 2020 10.1016/j.jbo.2020.100298 32642420 PMC7334391
68 Winnard PT Jr Vesuna F Bol GM Gabrielson KL Chenevix-Trench G Ter Hoeve ND van Diest PJ Raman V Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatment Cancer Lett 604 217260 2024 10.1016/j.canlet.2024.217260 39306228
69 Han Y Azuma K Watanabe S Semba K Nakayama J Metastatic profiling of HER2-positive breast cancer cell lines in xenograft models Clin Exp Metastasis 39 467 477 2022 10.1007/s10585-022-10150-1 35103869
70 Ye X Huang X Fu X Zhang X Lin R Zhang W Zhang J Lu Y Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis J Hematol Oncol 16 46 2023 10.1186/s13045-023-01442-4 37138326 PMC10155318
71 Zhong L Miller HD Zhang Y Jin B Ge D You Z Intra-arterial injection to create bone metastasis of prostate cancer in mice Am J Clin Exp Urol 8 93 100 2020 32929404 PMC7486538
72 Simmons JK Dirksen WP Hildreth BE III Dorr C Williams C Thomas R Breen M Toribio RE Rosol TJ Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo Prostate 74 1251 1265 2014 10.1002/pros.22838 25043424 PMC4216720
73 Abou DS Ulmert D Doucet M Hobbs RF Riddle RC Thorek DL Whole-Body and microenvironmental localization of Radium-223 in naïve and mouse models of prostate cancer metastasis J Natl Cancer Inst 108 djv380 2025 10.1093/jnci/djv380 PMC4849807 26683407
74 Pollard HB Levine MA Eidelman O Pollard M Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer In Vivo 24 249 255 2010 20554995 PMC9718485
75 Wang N Reeves KJ Brown HK Fowles AC Docherty FE Ottewell PD Croucher PI Holen I Eaton CL The frequency of osteolytic bone metastasis is determined by conditions of the soil, not the number of seeds; evidence from in vivo models of breast and prostate cancer J Exp Clin Cancer Res 34 124 2015 10.1186/s13046-015-0240-8 26480944 PMC4615337
76 Kaighn ME Narayan KS Ohnuki Y Lechner JF Jones LW Establishment and characterization of a human prostatic carcinoma cell line (PC-3) Invest Urol 17 16 23 1979 447482
77 Dai J Hensel J Wang N Kruithof-de Julio M Shiozawa Y Mouse models for studying prostate cancer bone metastasis Bonekey Rep 5 777 2016 10.1038/bonekey.2016.4 26916039 PMC4757481
78 Kozlowski JM Fidler IJ Campbell D Xu ZL Kaighn ME Hart IR Metastatic behavior of human tumor cell lines grown in the nude mouse Cancer Res 44 3522 3529 1984 6744277
79 Pettaway CA Pathak S Greene G Ramirez E Wilson MR Killion JJ Fidler IJ Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice Clin Cancer Res 2 1627 1636 1996 9816342
80 Stone KR Mickey DD Wunderli H Mickey GH Paulson DF Isolation of a human prostate carcinoma cell line (DU 145) Int J Cancer 21 274 281 1978 10.1002/ijc.2910210305 631930
81 Horoszewicz JS Leong SS Chu TM Wajsman ZL Friedman M Papsidero L Kim U Chai LS Kakati S Arya SK Sandberg AA The LNCaP cell line-a new model for studies on human prostatic carcinoma Prog Clin Biol Res 37 115 132 1980 7384082
82 Thalmann GN Anezinis PE Chang SM Zhau HE Kim EE Hopwood VL Pathak S von Eschenbach AC Chung LW Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer Cancer Res 54 2577 2581 1994 8168083
83 Sobel RE Sadar MD Cell lines used in prostate cancer research: A compendium of old and new lines-part 1 J Urol 173 342 359 2005 10.1097/01.ju.0000141580.30910.57 15643172
84 Guo Q Jin Y Lin M Zeng C Zhang J NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges Life Sci 348 122684 2024 10.1016/j.lfs.2024.122684 38710275
85 Zhou J Ottewell PD The role of IL-1B in breast cancer bone metastasis J Bone Oncol 46 100608 2024 10.1016/j.jbo.2024.100608 38800348 PMC11127524
86 Weilbaecher KN Guise TA McCauley LK Cancer to bone: A fatal attraction Nat Rev Cancer 11 411 425 2011 10.1038/nrc3055 21593787 PMC3666847
87 Shu ST Nadella MV Dirksen WP Fernandez SA Thudi NK Werbeck JL Lairmore MD Rosol TJ A novel bioluminescent mouse model and effective therapy for adult T-cell leukemia/lymphoma Cancer Res 67 11859 11866 2007 10.1158/0008-5472.CAN-07-1701 18089816 PMC2832603
88 Isaacs JT Heston WD Weissman RM Coffey DS Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT Cancer Res 38 4353 4359 1978 698976
89 Padalecki SS Guise TA Actions of bisphosphonates in animal models of breast cancer Breast Cancer Res 4 35 41 2002 10.1186/bcr415 11879558 PMC138714
90 Ooi LL Zheng Y Zhou H Trivedi T Conigrave AD Seibel MJ Dunstan CR Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis Bone 47 795 803 2010 10.1016/j.bone.2010.07.012 20638491
91 Yin JJ Mohammad KS Käkönen SM Harris S Wu-Wong JR Wessale JL Padley RJ Garrett IR Chirgwin JM Guise TA A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases Proc Natl Acad Sci USA 100 10954 10959 2003 10.1073/pnas.1830978100 12941866 PMC196909
92 Pulaski BA Ostrand-Rosenberg S Mouse 4T1 breast tumor model Curr Protoc Immunol Chapter 20: Unit 20.2 2001 doi: 10.1002/0471142735.im2002s39 18432775 10.1002/0471142735.im2002s39
93 Pulaski BA Ostrand-Rosenberg S Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Res 58 1486 1493 1998 9537252
94 Lelekakis M Moseley JM Martin TJ Hards D Williams E Ho P Lowen D Javni J Miller FR Slavin J Anderson RL A novel orthotopic model of breast cancer metastasis to bone Clin Exp Metastasis 17 163 170 1999 10.1023/A:1006689719505 10411109
95 Coleman RE Metastatic bone disease: Clinical features, pathophysiology and treatment strategies Cancer Treat Rev 27 165 176 2001 10.1053/ctrv.2000.0210 11417967
96 Feeley BT Liu NQ Conduah AH Krenek L Roth K Dougall WC Huard J Dubinett S Lieberman JR Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration Bone Miner Res 21 1571 1580 2006 10.1359/jbmr.060706 16995812
97 Miki T Yano S Hanibuchi M Sone S Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice Oncol Res 12 209 127 2000 10.3727/096504001108747701 11417746
98 Tannehill-Gregg SH Levine AL Nadella MV Iguchi H Rosol TJ The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice Clin Exp Metastasis 23 19 31 2006 10.1007/s10585-006-9008-z 16715352
99 Taube T Beneton MN McCloskey EV Rogers S Greaves M Kanis JA Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption Eur J Haematol 49 192 198 1992 10.1111/j.1600-0609.1992.tb00046.x 1464362
100 Nakano T Shimizu K Kawashima O Kamiyoshihara M Kakegawa S Sugano M Ibe T Nagashima T Kaira K Sunaga N Establishment of a human lung cancer cell line with high metastatic potential to multiple organs: Gene expression associated with metastatic potential in human lung cancer Oncol Rep 28 1727 1735 2012 10.3892/or.2012.1972 22922681
101 Yang S Dong Q Yao M Shi M Ye J Zhao L Su J Gu W Xie W Wang K Establishment of an experimental human lung adenocarcinoma cell line SPC-A-1BM with high bone metastases potency by (99m)Tc-MDP bone scintigraphy Nucl Med Biol 36 313 321 2009 10.1016/j.nucmedbio.2008.12.007 19324277
102 Gravina GL Mancini A Muzi P Ventura L Biordi L Ricevuto E Pompili S Mattei C Di Cesare E Jannini EA Festuccia C CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models Prostate 75 1227 1246 2015 10.1002/pros.23007 26073897
103 Wu TT Sikes RA Cui Q Thalmann GN Kao C Murphy CF Yang H Zhau HE Balian G Chung LW Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines Int J Cancer 77 887 894 1998 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z 9714059
104 Shevrin DH Kukreja SC Ghosh L Lad TE Development of skeletal metastasis by human prostate cancer in athymic nude mice Clin Exp Metastasis 6 401 409 1988 10.1007/BF01760575 3378377
105 Havens AM Pedersen EA Shiozawa Y Ying C Jung Y Sun Y Neeley C Wang J Mehra R Keller ET An in vivo mouse model for human prostate cancer metastasis Neoplasia 10 371 380 2008 10.1593/neo.08154 18392141 PMC2288546
106 Yang M Jiang P Sun FX Hasegawa S Baranov E Chishima T Shimada H Moossa AR Hoffman RM A fluorescent orthotopic bone metastasis model of human prostate cancer Cancer Res 59 781 786 1999 10029062
107 Fisher JL Schmitt JF Howard ML Mackie PS Choong PF Risbridger GP An in vivo model of prostate carcinoma growth and invasion in bone Cell Tissue Res 307 337 345 2002 10.1007/s00441-001-0503-x 11904770
108 Bonfil RD Dong Z Trindade Filho JC Sabbota A Osenkowski P Nabha S Yamamoto H Chinni SR Zhao H Mobashery S Prostate cancer-associated membrane type 1-matrix metalloproteinase: A pivotal role in bone response and intraosseous tumor growth Am J Pathol 170 2100 2111 2007 10.2353/ajpath.2007.060720 17525276 PMC1899437
109 Zou M Jiao J Zou Q Xu Y Cheng M Xu J Zhang Y Multiple metastases in a novel LNCaP model of human prostate cancer Oncol Rep 30 615 622 2013 10.3892/or.2013.2305 23446457
110 Corey E Quinn JE Bladou F Brown LG Roudier MP Brown JM Buhler KR Vessella RL Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells Prostate 52 20 33 2002 10.1002/pros.10091 11992617
111 Jantscheff P Ziroli V Esser N Graeser R Kluth J Sukolinskaya A Taylor LA Unger C Massing U Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model Clin Exp Metastasis 26 981 992 2009 10.1007/s10585-009-9288-1 19784785
112 Wetterwald A van der Pluijm G Que I Sijmons B Buijs J Karperien M Löwik CW Gautschi E Thalmann GN Cecchini MG Optical imaging of cancer metastasis to bone marrow: A mouse model of minimal residual disease Am J Pathol 160 1143 1153 2002 10.1016/S0002-9440(10)64934-6 11891210 PMC1867183
113 Sasaki SI Zhang D Iwabuchi S Tanabe Y Hashimoto S Yamauchi A Hayashi K Tsuchiya H Hayakawa Y Baba T Mukaida N Crucial contribution of GPR56/ADGRG1, expressed by breast cancer cells, to bone metastasis formation Cancer Sci 112 4883 4893 2021 10.1111/cas.15150 34632664 PMC8645723
114 Kim B Kim H Jung S Moon A Noh DY Lee ZH Kim HJ Kim HH A CTGF-RUNX2-RANKL axis in breast and prostate cancer cells promotes tumor progression in bone J Bone Miner Res 35 155 166 2020 10.1002/jbmr.3869 31505052
115 Yoneda T Michigami T Yi B Williams PJ Niewolna M Hiraga T Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma Cancer 88 2979 2988 2000 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U 10898341
116 Yi B Williams PJ Niewolna M Wang Y Yoneda T Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer Cancer Res 62 917 923 2002 11830552
117 Sun J Huang J Lan J Zhou K Gao Y Song Z Deng Y Liu L Dong Y Liu X Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer Cancer Cell Int 19 264 2019 10.1186/s12935-019-0986-8 31632198 PMC6788011
118 Hung JY Horn D Woodruff K Prihoda T LeSaux C Peters J Tio F Abboud-Werner SL Colony-stimulating factor 1 potentiates lung cancer bone metastasis Lab Invest 94 371 381 2014 10.1038/labinvest.2014.1 24468794
119 Liu H Cheng Q Xu DS Wang W Fang Z Xue DD Zheng Y Chang AH Lei YJ Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells Respir Res 21 287 2020 10.1186/s12931-020-01518-6 33129326 PMC7603767
120 Wang Q Zhao B Li J Zhao J Wang C Li Q Yang W Xu L Gong Y Qilian formula inhibits tumor cell growth in a bone metastasis model of lung cancer Integr Cancer Ther 22 15347354231217274 2023 10.1177/15347354231217274 38130184 PMC10748605